CBL-514 Cuts Visceral Fat 12% in Phase 2 Trials as 69.6% Lose 150 mL Subcutaneous Fat
Updated
Updated · ScienceDaily · Oct 11
CBL-514 Cuts Visceral Fat 12% in Phase 2 Trials as 69.6% Lose 150 mL Subcutaneous Fat
3 articles · Updated · ScienceDaily · Oct 11
Summary
MRI data from two phase 2 trials showed CBL-514 lowered visceral abdominal fat by 12.01% four weeks after the last injection, while placebo patients saw a 5.68% increase.
At a later follow-up, visceral fat in the CBL-514 group remained 10.45% below baseline versus an 11.76% rise with placebo, suggesting the effect persisted for weeks after treatment ended.
The injection works by triggering apoptosis in fat cells rather than just shrinking them; separately, 69.6% of treated participants lost at least 150 mL of subcutaneous fat by eight weeks, versus none on placebo.
Researchers said the drug was generally well tolerated, with mostly mild-to-moderate injection-site pain, swelling and redness and no serious adverse events reported.
Animal studies suggest CBL-514 could also limit weight regain after GLP-1 drugs such as tirzepatide are stopped, but that benefit has not yet been confirmed in humans as phase 3 trials begin.